What are the rates and disparities in the early uptake of GLP1-RA and SGLT2i among Medicare-insured older adults with T2D and newly diagnosed ASCVD or CHF?
There is a substantial deficit and significant racial and socioeconomic disparities in the delivery of guideline-recommended GLP1-RA and SGLT2i therapies among Medicare beneficiaries with T2D and incident ASCVD or CHF.
Among older adults with T2D and either ASCVD or CHF, initiation of GLP1-RA or SGLT2i was low, suggesting a substantial deficit in delivery of guideline-recommended care or treatment barriers. Individuals of Black and other race/ethnicity and those with higher area-level socioeconomic deprivation were less likely to initiate these medications.
Cromer et al. (Wed,) studied this question.